Bromazepam
Viewing r1 — May 9, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Bromazepam is a synthetic depressant of the benzodiazepine class. It occupies an intermediate position in the benzodiazepine duration landscape, between short-acting compounds like triazolam and long-acting diazepam.[1] Bromazepam is a positive allosteric modulator of the GABA-A, producing its effects by amplifying the brain's primary inhibitory signaling system.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
all benzodiazepines, alcohol, barbiturates +2 moreall benzodiazepines, alcohol, barbiturates, zolpidem, zopiclone show less
Synthesized at F. Hoffmann-La Roche as part of the systematic benzodiazepine program that followed Leo Sternbach's discovery of chlordiazepoxide in 1955,[3] bromazepam entered clinical use around 1974 and was marketed internationally under trade names including Lexotan, Lexomil, and Lectopam. The compound was never granted FDA marketing authorization in the United States, despite receiving DEA Schedule IV classification.[4] Prescribing has declined globally alongside the broader benzodiazepine deprescribing movement.
Subjective effects include anxiolysis, muscle relaxation, sedation, and disinhibition. At lower doses, the experience is characterized by a distinctive "activating" quality noted since the earliest clinical trials[5] — a loosening of inhibition and social tension rather than the blanketing drowsiness typical of the class. Cognitive blunting, anterograde amnesia, and motor impairment are common unsought effects at higher doses.
Bromazepam produces physical dependence with repeated use; acute lethality when taken alone is low.[6] All documented fatalities involved polydrug combinations with other CNS depressants, and abrupt cessation after chronic use risks seizures — persistent cognitive deficits have been documented months after withdrawal.[7] No published binding affinities, subunit-selectivity data, or human lethal dose exist for bromazepam specifically; mechanistic understanding rests on class-level evidence and functional studies.[8]
History[edit]
Discovery
Bromazepam was synthesized at F. Hoffmann-La Roche under the development code Ro 5-3350, part of the systematic benzodiazepine program that followed Leo Sternbach's discovery of chlordiazepoxide in 1955 and diazepam in 1963.[3] It was distinguished from earlier Roche benzodiazepines by the substitution of a pyridine ring at the 5-position — a deliberate exploration of heterocyclic variations within the benzodiazepine scaffold.[9]
Clinical development
The first controlled trials appeared in 1975. Sonne and Holm compared bromazepam to diazepam in patients with anxiety neurosis, finding patient preference favoring bromazepam.[9] Cassano and colleagues noted that bromazepam appeared to exert a "disinhibiting" or "activating" action unlike most other benzodiazepines in clinical use.[5] The compound was marketed internationally under trade names including Lexotan, Lexomil, and Lectopam.
Modern status
No active clinical trials are registered for bromazepam. Its evidence base dates entirely to the pre-registration era (1975–1996), positioning it as a legacy anxiolytic rather than a compound under active investigation. In jurisdictions where it remains available, prescribing has declined alongside the broader benzodiazepine deprescribing movement driven by evidence of long-term cognitive harm[10] and abuse liability.[6]
The name bromazepam follows standard benzodiazepine nomenclature: the "brom-" prefix denotes the bromine substituent at position 7, while "-azepam" identifies the 1,4-benzodiazepine scaffold. The compound is most widely recognized by its Roche trade name Lexotan in markets outside North America, and as Lectopam in Canada. Unlike benzodiazepines with significant street presence such as alprazolam and Diazepam, bromazepam has not acquired a widely used slang vocabulary in English-language drug culture.
Chemistry[edit]
Structural class
Bromazepam belongs to the 1,4-benzodiazepine class — the foundational scaffold of classical benzodiazepine anxiolytics. Its core structure consists of a benzene ring fused to a seven-membered diazepine ring containing a carbonyl group. The key structural distinction from prototypical benzodiazepines like diazepam is the replacement of the usual phenyl ring at position 5 with a pyridin-2-yl ring, making it a 5-heteroaryl benzodiazepine.
A bromine atom at position 7 provides the electron-withdrawing halogen substitution found in many clinically active members of the class.
Molecular identity
| Molecular formula | C₁₄H₁₀BrN₃O |
| Molecular weight | 316.15 g/mol |
The molecule contains three interconnected ring systems: a diazepinone (seven-membered, with nitrogen atoms at positions 1 and 4 and a lactam at position 2), a halogenated benzene ring, and a pyridine ring attached at position 5. The lactam N–H and methylene group distinguish it from N-alkylated analogs.
Stereochemistry
Bromazepam contains no chirality centers and does not exist as stereoisomers.
Physical properties
Bromazepam is a white to off-white crystalline powder with low water solubility. Pharmaceutical formulations use the free base in tablet and oral solution form. Equivalent bioavailability between liquid and solid formulations has been confirmed.[12]
Pharmacology[edit]
Mechanism of action
Bromazepam enhances the activity of GABA — the brain's primary inhibitory neurotransmitter — by binding an allosteric site on the GABA-A. Rather than activating the receptor directly, it increases the frequency with which the receptor's chloride channel opens when GABA is already present. This produces dose-dependent anxiolysis, sedation, muscle relaxation, and anticonvulsant effects.
The mechanism is confirmed by two independent lines of evidence. The benzodiazepine antagonist flumazenil completely blocks bromazepam's anxiolytic effects,[2] and mice with altered GABA-A receptor subunit expression show reduced response to the drug.[8]
At the spinal cord level, bromazepam enhances inhibitory nerve signaling that reduces muscle tension — an effect that depends on intact GABA levels and is abolished when GABA is depleted.[13]
Pharmacokinetics
Oral bioavailability is approximately 84%.[4]safety citation needed Peak blood levels are reached in about 2.3 hours when fasted, delayed slightly with food. Food also reduces peak concentration and overall drug exposure.[14]
Bromazepam is metabolized in the liver through oxidation. Its primary active metabolite, 3-hydroxybromazepam, retains pharmacological activity and has a similar half-life to the parent compound.[4][15] Elimination half-life is 20–30 hours in healthy young adults.[1]
In elderly individuals, drug levels rise higher, clearance is roughly halved, and a greater proportion circulates unbound to proteins — all supporting dose reduction in older populations.[1][16]
Potency equivalence
The standard equivalence is 3 mg bromazepam ≈ 5 mg diazepam,[4] supported by clinical trial dosing in which bromazepam 18 mg/day and diazepam 15 mg/day were used as equivalent comparators.[17]
Neuroscience[edit]
Where it acts
Bromazepam amplifies inhibitory signaling across multiple brain regions. In the amygdala, enhanced GABA activity dampens the output of fear-generating circuits, producing anxiolysis.inferred In the hippocampus, inhibition of memory-encoding circuits produces the anterograde amnesia characteristic of benzodiazepines at moderate-to-high doses.[18] At the spinal cord, enhancement of presynaptic inhibition underlies the muscle relaxant effect.[13]
The "activating" quality noted in early clinical trials[5] may reflect a dose-dependent shift: at lower doses, anxiolysis predominates through inhibition of fear circuits, while at higher doses, broader cortical sedation overtakes the initial clarity.
Chronic adaptation and risk
Repeated exposure triggers maladaptive changes: GABA-A subunits downregulate while excitatory glutamate systems become sensitized.[6] This rebalancing underlies both tolerance (the drug works less well) and the dangerous withdrawal state (seizures, rebound effect anxiety) that follows abrupt cessation.
Long-term cognitive impairment persisting six months or more after stopping use suggests changes that go beyond simple receptor shifts.[7] Prospective cohort data associate benzodiazepine use with a 60% increased risk of dementia,[10] though whether the drugs cause neurodegeneration or are prescribed to people already developing it remains unresolved.
Unanswered questions include whether bromazepam's unusual pyridine ring confers any functional selectivity among GABA-A receptor subtypes — no binding data exist to test this. The neural basis of the "activating" quality reported in early trials remains unexplained. Whether cognitive function fully recovers after long-term benzodiazepine use, or whether extended exposure establishes permanent deficits, is not yet known.
Subjective Effects[edit]
At lower doses, bromazepam produces a distinctive clarity — anxiolysis without the heavy sedation typical of many benzodiazepines. This "activating" quality, documented since the earliest clinical trials,[5] manifests as a loosening of inhibition and social tension rather than drowsiness. As dose increases, sedation and cognitive blunting overtake the initial lightness, and the experience converges with the general benzodiazepine profile. Prior tolerance significantly shapes the experience: habituated users perceive primarily sedation rather than relief.
Compared to diazepam at equipotent doses (3 mg bromazepam ≈ 5 mg diazepam), bromazepam is reported as less soporific at anxiolytic doses. Relative to shorter-acting alprazolam, the longer half-life produces more sustained effects with less interdose rebound effect but greater next-day residual impairment.
Effect Grid
Full anxiety suppression with pronounced muscle relaxation and moderate sedation in naive users. Emotional suppression becomes evident — emotional responses feel dampened, flattened. Thought deceleration is noticeable; analysis suppression makes complex reasoning effortful. Disinhibition is evident in social behavior.
Motor control impairment is clearly apparent — coordination is visibly reduced. Anterograde amnesia begins: events during the experience may not be encoded into long-term memory. Dizziness is possible when standing. Sedation builds progressively over 2–3 hours.
Equivalent to approximately 5–10 mg diazepam. Functional impairment is significant despite possible delusions of sobriety. Do not drive or operate machinery.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Spatial disorientation · Visual haze / noise · Visual processing suppression
Bodily heaviness · Body high · Dizziness · Breathing alteration · Nystagmus (eye wobbles) · Dry mouth · Tactile euphoria · Headache · Nausea
Nystagmus (eye wobbles) · Dry mouth · Tactile euphoria · Headache · Nausea
Thought deceleration · Analysis suppression · Focus suppression · Information processing suppression · Motivation suppression · Creativity suppression · Memory fragmentation · Language suppression · Thought disorganization · Cognitive euphoria · Confusion · Compulsive redosing urge · Suggestibility enhancement · Amnesia
Information processing suppression · Motivation suppression · Creativity suppression · Memory fragmentation · Language suppression · Thought disorganization · Cognitive euphoria · Confusion · Suggestibility enhancement · Amnesia
Irritability · Anxiety · Emotional lability
Craving · Sociability suppression · Depersonalization · Derealization
Timeline
Initial absorption begins. A subtle shift in affect — first hints of anxiolysis as background tension softens. No overt sedation or motor effects yet.
Progressive anxiolysis develops over 15–120 minutes. Muscle relaxation becomes apparent. The 'activating' disinhibiting quality is most noticeable during this phase.
Maximum anxiolytic and sedative effects. Motor control impairment and anterograde amnesia most pronounced. Duration is strongly dose-dependent — 2 hours at threshold doses, up to 12 hours at heavy doses.
Effects wane gradually. Baseline anxiety begins returning. Sedation may persist longer than anxiolysis.
Residual sedation and mild cognitive fog due to 20–30 hour elimination half-life. Next-day psychomotor impairment is common. Subtle anxiolysis may linger.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- High
- Withdrawal
- Severefatal risk
- Tolerance buildup
- moderate
- Tolerance reset
- 3 weeks
- Physical
- High
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- all benzodiazepines · alcohol · barbiturates
Toxicity
Acute toxicity
Bromazepam shares the low acute lethality characteristic of benzodiazepines when taken alone. No human lethal dose has been established. Protracted deep coma following bromazepam poisoning alone has been reported, with investigators noting that bromazepam intoxication is "very common but surprisingly rarely reported" in the literature.[19]
Polydrug fatality risk
All identified fatal cases involved combinations with other central nervous system depressants. The principal danger is co-ingestion with alcohol, opioids, antidepressants, or antipsychotics, which produce additive-to-synergistic respiratory and cardiovascular depression. Fatal overdoses involving tramadol[20] and multi-drug cocktails[21] have been documented. In one case, a highly supratherapeutic blood level was survived when concurrent stimulant use partially offset respiratory depression.[22]
Chronic toxicity
Benzodiazepine use is associated with a 60% increased risk of dementia in prospective cohort data.[10] Persistent cognitive deficits across most domains have been documented at six months or more after cessation, with incomplete recovery.[7]
Psychological risks
Bromazepam produces anterograde amnesia at moderate-to-high doses — the inability to form new memories during intoxication.[18] Delusions of sobriety — the subjective conviction of being unimpaired despite measurable cognitive and motor deficits — represent a significant harm vector for driving, decision-making, and redosing.
Disinhibition, noted as a distinguishing feature in early trials,[5] may compound these risks. Paradoxical reactions including agitation and aggression occur in a small proportion of users, particularly elderly individuals. Rebound anxiety that exceeds baseline severity after cessation creates a self-reinforcing cycle of continued use.
Tolerance and dependence
Repeated use produces tolerance through two mechanisms: GABA-A subunit downregulation (reducing the drug's effectiveness) and compensatory sensitization of excitatory glutamate systems (shifting brain chemistry toward hyperexcitability).[6] Cross-tolerance exists between all benzodiazepines and between benzodiazepines and alcohol.[18]
Tolerance to sedation typically develops within one to two weeks; tolerance to anxiolytic effects develops more slowly.inferred Physical dependence produces a withdrawal upon cessation that ranges from rebound anxiety, insomnia, and tremor to life-threatening seizures and delirium.
In a withdrawal-management trial using bromazepam 3–6 mg/day as the reference compound, 65.5% of patients were successfully withdrawn over six months.[23] Clinical management requires gradual tapering — typically 10–25% dose reduction every one to two weeks.[6]
Drug interactions
Pharmacokinetic
Fluvoxamine significantly impairs bromazepam clearance by inhibiting its liver metabolism, producing elevated blood levels.[24][25][26] Cimetidine reduces clearance by approximately 50%.[1] Propranolol extends the half-life modestly, likely by reducing liver blood flow.[1]
Pharmacodynamic
Alcohol: Additive GABA-A enhancement produces synergistic sedation and respiratory depression. This combination is implicated in the majority of benzodiazepine-related deaths.[22]
Opioids: Additive-to-synergistic respiratory depression. Fatal combined overdoses involving tramadol and bromazepam have been documented.[20]
Other CNS depressants: Antipsychotics,[27] sedating antidepressants, other benzodiazepines, and sleep medications all produce additive depression when combined with bromazepam.
Stimulants: Co-administration may partially offset respiratory depression but creates unpredictable toxicity.[22]
Contraindications
Absolute:
- Severe breathing difficulty — bromazepam worsens respiratory insufficiency by depressing central breathing drive
- Sleep apnea — pharyngeal muscle relaxation and reduced arousal response exacerbate obstructive episodes
- Myasthenia gravis — GABA-A enhancement compounds existing neuromuscular dysfunction
Relative:
- First trimester of pregnancy — class-level concern for birth defects; no bromazepam-specific data[15]
- Liver impairment — reduced clearance expected to produce elevated and prolonged drug exposuresafety citation needed
- History of substance use disorder — reinforcement potential and compulsive redosing liability
- Elderly individuals — clearance halved, peak levels increased, greater unbound drug fraction[1]
- Concurrent CNS depressant use — all fatal cases involved polydrug contexts
- Benzodiazepine hypersensitivity
Harm Reduction[edit]
Forms & Identification
Bromazepam circulates almost exclusively as pharmaceutical tablets — counterfeits are less common than with high-demand benzodiazepines like alprazolam, but unregulated supply exists in jurisdictions where the compound is not marketed domestically (notably the United States). Tablets obtained outside legitimate pharmacy channels cannot be assumed to contain bromazepam at the labeled dose or at all.
Reagent testing has limited utility for confirming benzodiazepine identity, as most colorimetric reagents do not distinguish between individual benzodiazepines. Quantitative analysis or immunoassay-based testing provides more reliable identification.
Guidelines
- Start with the lowest available dose (1.5 mg) if benzodiazepine-naive, and wait at least three hours before considering redosing — the long half-life means effects accumulate
- Avoid redosing based on perceived sobriety; benzodiazepine intoxication characteristically impairs self-assessment of impairment
- Do not drive or operate machinery — motor and cognitive impairment outlasts subjective awareness of the drug
- Avoid use on consecutive days; even a few days of regular use initiates neuroadaptation toward dependence
- If using for anxiety management, treat as a short-term bridge (days, not weeks) and have an exit plan before starting
- Keep doses consistent — do not escalate to chase diminished effects, as this accelerates dependence
Aftercare & Integration
The long half-life of bromazepam means residual impairment can persist into the following day. Avoid demanding cognitive tasks, driving, or important decisions for at least 24 hours after a dose. Sleep quality may be altered — benzodiazepines suppress slow-wave sleep even when they feel like they help with insomnia.
For those using bromazepam to manage anxiety, reflect on whether the drug is addressing the symptom or replacing coping mechanisms. If use extends beyond a few days, discuss a structured plan with a healthcare provider before dependence develops.
Recovery & Support
Benzodiazepine dependence is a well-recognized medical condition with established treatment pathways. Abrupt cessation after regular use is dangerous — withdrawal seizures can be life-threatening. A supervised taper, typically reducing dose by 10–25% every one to two weeks, is the standard medical approach.
Recovery timelines vary widely. Acute withdrawal symptoms may persist for weeks; post-acute symptoms including rebound effect anxiety, insomnia, and cognitive difficulty can continue for months. Support resources include the Benzodiazepine Information Coalition (benzoinfo.com), SMART Recovery, and local addiction medicine services. Professional guidance is strongly recommended for anyone who has used benzodiazepines daily for more than two weeks.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
Signs that distinguish a medical emergency from uncomfortable intoxication: unresponsive to voice and physical stimulation, breathing rate below 8 breaths per minute or irregular gasping, blue or grey discoloration of lips and fingertips, seizures, or loss of consciousness.
Immediate steps:
- Call emergency services immediately if breathing is compromised or the person is unresponsive
- Place the person in the recovery position (on their side, airway clear) if unconscious but breathing
- Do not induce vomiting
- Do not leave an unconscious person alone
- Monitor breathing continuously until help arrives
What to tell the dispatcher:
State the substance (bromazepam or benzodiazepine), approximate amount taken, time of ingestion, any other substances consumed, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Reversal agent:
Flumazenil is a specific benzodiazepine antagonist that can reverse respiratory depression and sedation in hospital settings. It is not available over the counter and carries a risk of triggering seizures in dependent individuals — its use is a clinical decision, not a field intervention.
Legal Status[edit]
Bromazepam is internationally controlled under the United Nations Convention on Psychotropic Substances (Schedule IV), reflecting the standard classification applied to clinically used benzodiazepines. Domestic scheduling varies by jurisdiction, with notable differences in clinical availability.
The most unusual regulatory situation is in the United States, where bromazepam is DEA Schedule IV (code number 2748) but has never received FDA marketing authorization — making it legally controlled but clinically unavailable as a domestic prescription product.[4]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| International (UN) | Convention on Psychotropic Substances, Schedule IV | Standard benzodiazepine international control |
| United States | DEA Schedule IV (CSN 2748) | No FDA marketing authorization; clinically unavailable domestically |
| United Kingdom | Class C, Schedule 4 Part 1 (Misuse of Drugs Act 1971) | Controlled; no active marketing authorization[28] |
| Australia | Schedule 4 (Prescription Only Medicine) | TGA-registered as Lexotan 3 mg and 6 mg;[29] PBS-listed for short-term use (2–4 weeks)[30] |
| Canada | Schedule IV (Controlled Drugs and Substances Act) | Marketed as Lectopam; prescription required |
| Germany | Prescription (BtMG equivalent for BZDs) | Available as branded generics; standard benzodiazepine controls |
| France | Prescription (Liste I) | Marketed as Lexomil; standard dispensing restrictions |
| Brazil | Prescription (Lista C1, ANVISA) | Marketed as Lexotan; controlled dispensing |
references
- [1]
- [2] ^abVieira MPS et al. (2022) First evaluation of the anxiolytic-like effects of a bromazepam-palladium complex in mice. — Journal of Inorganic Biochemistry doi:10.1016/j.jinorgbio.2022.112012
- [3] ^abWick JY (2013) The history of benzodiazepines — The Consultant Pharmacist doi:10.4140/tcp.n.2013.538
- [4]
- [5]
- [6]